Testimonial accelopment’s high standard of professionalism and expertise were key in ensuring we maximised our chances of success in receiving funding.
Prof. Ira Haraldsen
AI-Mind Project Coordinator
Oslo University Hospital, Norway

<< Projects

AI-Mind

Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment

More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached. AI-Mind will radically shorten this journey to 1 week through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk. Our AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools. The AI-Mind Connector identifies dysfunctional brain networks. The AI-Mind Predictor assesses dementia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables. Our aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform. The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical centres, who closely collaborate with 3 SMEs contributing unique technologies, an established data governance body-DNV GL, and Alzheimer Europe. Together, they plan to deliver a medical device of class 2b that can reach TRL7 by the end of the project. AI-Mind represents a major step forward in the risk assessment of dementia. Clinicians will promptly advise therapies to delay the onset of disease, and patients will enjoy independent lives for longer. By offering a globally accessible, cheap and precise tool for dementia prediction, AI-Mind will improve the health care system and boost innovation by shifting the R&D of pharmaceutical organisations and other companies to preventive diagnostic methods and therapies for dementia.

This project contributes to the UN Sustainable Development Goals (SDGs) 3 and 9.

Coordinator:
Oslo universitetssykehus, NO

Partners:

Funded Project




AreaLife Sciences
ProgrammeFP7-SME
Duration01.10.2013 - 31.12.2015
Budget1.1 million euro
More


Strategic Grant Planning (SGP)



We will support you in identifying the best funding scheme for your idea and in planning your grant applications for the upcoming years. We have expertise from the Horizon 2020 programme, including MSCA ITNs, FET OPEN, EIC accelerator (formerly SME instrument) to Eurostar and national funding. SGP is individualised and based on your needs. You will interact with one of our experts via online and a half- or full-day face-to-face meetings.

More

Team



For me it is rewarding to help businesses and scientific institutions creating the future. We break down barriers towards a world full of knowledge, research and innovation.

Andreia Cruz
Research & Innovation Project Manager